Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation

Leiter, Lawrence; Shestakova, Marina; Trubitsyna, Natalya; Piletic, Milivoj; Satman, İlhan

doi:10.1016/j.diabres.2015.11.001

Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation

Leiter L. A., Shestakova M. V., Trubitsyna N. P., Piletic M., Satman I.

DIABETES RESEARCH AND CLINICAL PRACTICE, cilt.112, ss.50-56, 2016 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 112
Basım Tarihi: 2016
Doi Numarası: 10.1016/j.diabres.2015.11.001
Dergi Adı: DIABETES RESEARCH AND CLINICAL PRACTICE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.50-56
Anahtar Kelimeler: Type 2 diabetes, Gliclazide, Glycemic control, Treatment adherence, TYPE-2 DIABETES-MELLITUS, INSULIN SECRETAGOGUES, MEDICATION ADHERENCE, FOLLOW-UP, MANAGEMENT, MORTALITY, CARE, HYPERGLYCEMIA, HYPOGLYCEMIA, OUTCOMES
İstanbul Üniversitesi Adresli: Evet

Özet

Aim: The 6-months titration profile of a new scored gliclazide modified release (MR) formulation (MR 60 mg) was explored in individuals with type 2 diabetes.